admin – page 2 – eisai china lnc.-开元体育官网下载手机版

 admin – page 2 – eisai china lnc.-开元体育官网下载手机版

entries by

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the european medicines agency (ema) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate (product name: lenvima® / kisplyx®, “lenvatinib”), in combination with anti-pd-1 therapy pembrolizumab (brand name: keytruda®), developed by merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) as a treatment f or patients with advanced renal cell carcinoma (rcc) and advanced endometrial carcinoma (ec), respectively.

eisai china policy on submission of ideas: 1. eisai china holdings ltd., its affiliates and subsidiaries (collectively, ” eisai china”) are committed to protecting the privacy of the information collected from external individuals and organizations through eisai china online opportunity submission process. information here refers to personal identifiable information and other personal data, as well […]

eisai china holdings ltd. / eisai china inc.   shanghai branch address: 39-40th floor, park place, no.1601 nanjing xi road, shanghai, p.r.c tel: 021–24192888    fax: 021–24192891    zip code: 200040 suzhou factory address: 168# xingpu road,suzhou industrial park,jiangsu province p.r.c tel: 86-512-69566776     fax: 86-512-62576776     zip code: 215126 beijing branch address: 2303-2306 room, 23th floor, sk building, no.a 6 jianguomenwai […]

accessibility features of the site

        eisai china is committed to making this website accessible to the broadest possible audience, regardless of technology or physical capability. to this end, we are working constantly to improve the overall usability of the site, using many of the existing international standards for accessibility on the internet as guidelines. images: • […]

legal notice

legal notice of eisai china inc. website please read the following legal notice carefully prior to using the corporate website (“the website”) of eisai china inc. (“eisai”), which includes 开元体育官网下载手机版 copyrights, trademarks and domain name, privacy, disclaimers, links, applicable laws and versions. by accessing the website, you agree and accept all terms of this legal notice, […]

privacy policy

eci personal information protection policy 1、eisai abides by all chinese laws and regulations on the provision and protection of personal information. 2、eisai obtains, processes and applies personal information lawfully. 3、eisai collects personal information using appropriate methods for specified purposes of use and does not use it in a way that is contrary with those purposes. […]


eisai china inc. is a pharmaceutical company wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company headquartered in tokyo, with strong r&d capabilities. eisai has been smoothly developing its business in china since the early 1990s, eisai china, inc. currently promotes more than 10 pharmaceutical brands in china, specializing in the central nervous […]


· manufacturing as part of eisai’s global manufacturing system, eisai suzhou factory carries out all manufacturing processes from local production of tablets, capsules and injections to the repackaging of the imported semi-products. the factory sits on a sprawling land of 25,000m2 in suzhou industrial park and is equipped with state-of-the-art machineries. in 2004, the total investment […]

quality assurance

in line with eisai’s general policy on product quality (i.e. “the quality of every single tablet, capsule and ampoule that we produce is integral to the life of the patient”), eisai china, inc. is committed to ensuring that only high quality products come out of its suzhou factory. to this end, all manufacturing operations in the […]